Retraction notice to “miR-4295 promotes cell proliferation and invasion in anaplastic thyroid carcinoma via CDKN1A” (Biochemical and Biophysical Research Communications (2015) 464(4) (1309–1313), (S0006291X15303594), (10.1016/j.bbrc.2015.07.128));MiR-4295 promotes cell proliferation and invasion in anaplastic thyroid carcinoma via CDKN1A

Biochemical and Biophysical Research Communications

Volumn 464, Issue 4, 2015, Pages 1309-1313

  Shao, Mingchen ^a,b   Geng, Yiwei ^a,b   Lu, Peng ^c   Xi, Ying ^a,b   Wei, Sidong ^c   Wang, Liuxing ^a,b   Fan, Qingxia ^a,b   Ma, Wang ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c People's Hospital of Zhengzhou   (China)

Author keywords

Anaplastic thyroid carcinoma; CDKN1A; miR 4295

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MICRORNA; MICRORNA 4295; TRANSCRIPTOME; UNCLASSIFIED DRUG; CDKN1A PROTEIN, HUMAN; MIRN4295 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; CELL INVASION; CELL INVASION ASSAY; CELL MIGRATION; CELL MIGRATION ASSAY; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; PRIORITY JOURNAL; REPORTER GENE; THYROID CARCINOMA; TUMOR PROMOTION; WESTERN BLOTTING; METABOLISM; PATHOLOGY; THYROID TUMOR; TUMOR CELL LINE; TUMOR INVASION;

CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS;

EID: 84940459258     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2018.11.198     Document Type: Erratum

References (20)

1. A.R. Shaha Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer Laryngoscope 114 2004 393 402
2. A. Hebrant, S. Floor, M. Saiselet, A. Antoniou, A. Desbuleux, B. Snyers, C. La, N. de Saint Aubain, E. Leteurtre, G. Andry, and C. Maenhaut miRNA expression in anaplastic thyroid carcinomas PLoS One 9 2014 e103871
3. D.P. Bartel MicroRNAs: target recognition and regulatory functions Cell 136 2009 215 233
4. Q. Cheng, X. Zhang, X. Xu, and X. Lu MiR-618 inhibits anaplastic thyroid cancer by repressing XIAP in one ATC cell line Ann. Endocrinol. Paris 75 2014 187 193
5. Y. Xiong, L. Zhang, and E. Kebebew MiR-20a is upregulated in anaplastic thyroid cancer and targets LIMK1 PLoS One 9 2014 e96103
6. Y. Zhang, W.Q. Yang, H. Zhu, Y.Y. Qian, L. Zhou, Y.J. Ren, X.C. Ren, L. Zhang, X.P. Liu, C.G. Liu, Z.J. Ming, B. Li, B. Chen, J.R. Wang, Y.B. Liu, and J.M. Yang Regulation of autophagy by miR-30d impacts sensitivity of anaplastic thyroid carcinoma to cisplatin Biochem. Pharmacol. 87 2014 562 570
7. L. Zhang, B. Xu, Y. Qiang, H. Huang, C. Wang, D. Li, and J. Qian Overexpression of deubiquitinating enzyme USP28 promoted non-small cell lung cancer growth J. Cell. Mol. Med. 19 2015 799 805
8. V. Ambros, B. Bartel, D.P. Bartel, C.B. Burge, J.C. Carrington, X. Chen, G. Dreyfuss, S.R. Eddy, S. Griffiths-Jones, M. Marshall, M. Matzke, G. Ruvkun, and T. Tuschl A uniform system for microRNA annotation RNA 9 2003 277 279
9. A. Kasprzyk, D. Keefe, D. Smedley, D. London, W. Spooner, C. Melsopp, M. Hammond, P. Rocca-Serra, T. Cox, and E. Birney EnsMart: a generic system for fast and flexible access to biological data Genome Res. 14 2004 160 169
10. M. Tarailo-Graovac, and N. Chen Using RepeatMasker to identify repetitive elements in genomic sequences Curr. Protoc. Bioinform. 2009 Chapter 4, Unit 4 10
11. M.D. Paraskevopoulou, G. Georgakilas, N. Kostoulas, M. Reczko, M. Maragkakis, T.M. Dalamagas, and A.G. Hatzigeorgiou DIANA-LncBase: experimentally verified and computationally predicted microRNA targets on long non-coding RNAs Nucleic Acids Res. 41 2013 D239 D245
12. B. John, A.J. Enright, A. Aravin, T. Tuschl, C. Sander, and D.S. Marks Human microRNA targets PLoS Biol. 2 2004 e363
13. B.P. Lewis, C.B. Burge, and D.P. Bartel Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets Cell 120 2005 15 20
14. J. Li, X. Kong, J. Zhang, Q. Luo, X. Li, and L. Fang MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer Cancer Cell Int. 13 2013 7
15. W.K. Wu, C.W. Lee, C.H. Cho, D. Fan, K. Wu, J. Yu, and J.J. Sung MicroRNA dysregulation in gastric cancer: a new player enters the game Oncogene 29 2010 5761 5771
16. J. Miao, S. Wu, Z. Peng, M. Tania, and C. Zhang MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects Tumour Biol. 34 2013 2093 2098
17. K.W. Overton, S.L. Spencer, W.L. Noderer, T. Meyer, and C.L. Wang Basal p21 controls population heterogeneity in cycling and quiescent cell cycle states Proc. Natl. Acad. Sci. U. S. A. 111 2014 E4386 E4393
18. T. Abbas, and A. Dutta p21 in cancer: intricate networks and multiple activities Nat. Rev. Cancer 9 2009 400 414
19. N.A. Warfel, and W.S. El-Deiry p21WAF1 and tumourigenesis: 20 years after Curr. Opin. Oncol. 25 2013 52 58
20. J. Kim, S. Bae, S. An, J.K. Park, E.M. Kim, S.G. Hwang, W.J. Kim, and H.D. Um Cooperative actions of p21WAF1 and p53 induce slug protein degradation and suppress cell invasion EMBO Rep. 15 2014 1062 1068